6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Medical treatment of Cushing’s disease: Overview and recent findings

      review-article

      Read this article at

      ScienceOpenPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cushing’s disease, due to pituitary adrenocorticotropic hormone (ACTH) hypersecretion, is the most common etiology of spontaneous excess cortisol production. The majority of pituitary tumors causing Cushing’s disease measure <1 cm and the excess morbidity associated with these tumors is mostly due to the effects of elevated, nonsuppressible, ACTH levels leading to adrenal steroid hypersecretion. Elevated circulating cortisol levels lead to abnormal fat deposition, hypertension, diabetes, coronary artery disease, osteoporosis, muscle weakness and psychological disturbances. At experienced centers, initial surgical remission rate via transnasal, transphenoidal resection approaches 80% for tumors less than 1 cm, but may be as low as 30% for larger lesions and long-term recurrence in all groups approaches 25%. Residual disease may be managed with more radical surgery, pituitary-directed radiation, bilateral adrenalectomy, or medical therapy. This paper addresses current and novel therapies in various stages of development for Cushing’s disease.

          Related collections

          Author and article information

          Journal
          Int J Gen Med
          International Journal of General Medicine
          Dove Medical Press
          1178-7074
          2009
          29 December 2009
          : 2
          : 209-217
          Affiliations
          [1 ]Department of Medicine
          [2 ]Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
          Author notes
          Correspondence: Anthony P Heaney, David Geffen School of Medicine at UCLA, 650 Charles E Young Drive South, 9-240N Factor Building, Los Angeles, CA 90095, USA, Tel +1 310 267 4980, Email aheaney@ 123456mednet.ucla.edu
          Article
          ijgm-2-209
          2840568
          20360906
          9d61b2a5-90b2-47f2-b61c-2988f79a300b
          © 2009 Praw and Heaney, publisher and licensee Dove Medical Press Ltd.

          This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

          History
          : 20 October 2009
          Categories
          Review

          Medicine
          treatment,pasireotide,ppar-γ,cushing’s disease,11 β-hydroxysteroid dehydrogenase inhibitors,dopamine agonists

          Comments

          Comment on this article